PDCD1 and non-small cell lung carcinoma: Previous molecular interactions aside, the observation of synergetic effects in patients with NSCLC treated with anti‐PD‐1 blocker plus chemotherapy seemed to accord with the hypothesis that chemotherapy may upregulate PD‐L1 expression level as well as promote antitumor immunity.